Joe certainly gives shareholders a lot of opportun

Joe certainly gives shareholders a lot of opportunity to ask questions and offers some pretty in depth responses. I think it’s helpful for investors to relisten to the last two conference calls that are on Generex’s website. It must be very difficult to undergo a one year SEC deep dive audit on the 2019 10K that Joe informed all shareholders about, more SEC comments regarding dividends to shareholders, and more SEC comments on the NGIO 10G. And with those audits with comments needing addressing the company couldn’t have S1s approved to raise the capital to do anything. It’s all very well detailed on the last calls.

The delays caused by the SEC really hurt us all, but I think Joe has been very open about that. However, he and Generex have cleared the 10K audit, and all of the comments. Bentai and that deal has now solved the issue of funding the Ii-Key/Covid vaccine so things should move quicker. Hopefully, we see the FDA IND filed in the remainder of this year and human trials begin in February or so. 2020 was hard on all, and for Generex a pandemic halted VA Hospitals and needed revenue, all while undergoing a huge audit, but as I said the company made us aware of that in numerous calls.